The overall rate of MSI-H or indeterminate MSI in soft-tissue sarcomas was 5.7% (45/785 patients), and 2 of these 45 patients had LS due to MSH2 pathogenic variants. This evidence concerns the gene MSH2 and soft tissue sarcoma.